# Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19

> **NCT05185284** · PHASE3 · COMPLETED · sponsor: **Promomed, LLC** · enrollment: 217 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Favipiravir
- **DRUG:** Favipiravir
- **DRUG:** Remdesivir

## Key facts

- **NCT ID:** NCT05185284
- **Lead sponsor:** Promomed, LLC
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-11
- **Primary completion:** 2021-12-30
- **Final completion:** 2021-12-30
- **Target enrollment:** 217 (ACTUAL)
- **Last updated:** 2022-01-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05185284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05185284, "Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05185284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*